Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes

被引：0
|
作者：
Pirro, V. [1 ]
Willency, J. A. [1 ]
Wilson, J. M. [1 ]
Roth, K. D. [1 ]
Lin, Y. [1 ]
Collins, K. A. L. [1 ]
Ruotolo, G. [1 ]
Haupt, A. [1 ]
Newgard, C. B. [2 ]
Duffin, K. L. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Duke Mol Physiol Inst, Durham, NC USA
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
146
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [21] GIP and GLP-1 receptor agonism in the therapy of type 2 diabetes with a focus on tirzepatide
    Nauck, Michael A.
    Blueher, Matthias
    Meyhoefer, Sebastian M.
    Heitmann, Elke
    Goergens, Sven W.
    [J]. DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (06) : 475 - 487
  • [22] Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)
    Ludvik, Bernhard
    Giorgino, Francesco
    Jodar, Esteban
    Frias, Juan Pablo
    Lando, Laura Fernandez
    Brown, Katelyn
    Bray, Ross
    Rodriguez, Angel
    [J]. DIABETES, 2021, 70
  • [23] The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
    Wilson, J. M.
    Nikooienejad, A.
    Bowsman, L. M.
    Schroeder, J. M.
    Hamlin, D. M.
    Robins, D. A.
    Riesmeyer, J. S.
    Haupt, A.
    Duffin, K. L.
    Ruotolo, G.
    [J]. DIABETOLOGIA, 2019, 62 : S558 - S559
  • [24] Efficacy and safety of tirzepatide, a dual GIP/GLP-1 receptor agonist, compared to insulin degludec in patients with type 2 diabetes (SURPASS-3)
    Ludvik, B.
    Giorgino, F.
    Jodar, E.
    Frias, J. P.
    Lando, L. Fernandez
    Brown, K.
    Bray, R.
    Rodriguez, A.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 245 - 245
  • [25] Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan M.
    Duffin, Kevin L.
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    [J]. DIABETES, 2019, 68
  • [26] THE DUAL GIP AND GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES (T2D)
    Wilson, J.
    Nikooienejad, A.
    Lin, Y.
    Robins, D.
    Roell, W.
    Riesmeyer, J.
    Haupt, A.
    Duffin, K.
    Ruotolo, G.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A164 - A165
  • [27] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [28] The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
    Frias, Juan Pablo
    Bastyr, Edward J., III
    Vignati, Louis
    Tschoep, Matthias H.
    Schmitt, Christophe
    Owen, Klara
    Christensen, Rune Haubo
    DiMarchi, Richard D.
    [J]. CELL METABOLISM, 2017, 26 (02) : 343 - +
  • [29] The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Transiently Delays Gastric Emptying Similarly to a Selective Long-Acting GLP-1 Receptor Agonist
    Urva, Shweta
    Nauck, Michael A.
    Coskun, Tamer
    Cui, Xuewei
    Haupt, Axel
    Benson, Charles
    Loghin, Corina
    [J]. DIABETES, 2019, 68
  • [30] The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist
    Urva, S.
    Nauck, M. A.
    Coskun, T.
    Cui, X.
    Haupt, A.
    Benson, C. T.
    Loghin, C.
    [J]. DIABETOLOGIA, 2019, 62 : S58 - S58
12345